RU2486896C1 - Method of obtaining medication for activation of non-specific resistance, prevention and therapy of diseases in young agricultural animals - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biotechnology and veterinary medicine. Method of obtaining immunotropic medication for prevention and treatment of inflammatory processes in agricultural animals includes mixing 90 wt.fr. of 0.2-0.3% agar suspension, 2.5 wt.fr. of concentrate of refined polysaccharide complex of yeast cells, 3.5 wt.fr. (-)2,3,5,6-tetrahydro-6- phenylimidazo -[2,1-b]- thiazole of hydrochloride and 0.2 wt.fr. of formalin, with additional introduction of 5.0 mln U of antibiotic amoxicillin in mixing and bringing volume of medicine to 100 wt.fr.

EFFECT: invention ensures increase of non-specific resistance and immunogenesis in prevention and treatment of diseases in animals.

2 tbl, 4 ex

Description

The invention relates to the field of biotechnology and veterinary medicine, and in particular to methods for producing drugs for the prevention and treatment of diseases of young farm animals, increasing nonspecific resistance and immunogenesis of the body.

A known method of obtaining a biologically active preparation from yeast (SU 1808331 A1, A61K 35/72, 04/15/93) in the form of a purified polysaccharide complex with immunostimulating activity. Immobilization of yeast cell polysaccharides in an agar gel (TU 10.07.236-91 for the production of Dostim) or in a 10-14% aqueous-salt solution of polyvinylpyrrolidone (RU 2137480 C1, A61K 31/79, 35/72, 09/20/99) increases the immunostimulating activity of drugs.

The closest analogue (prototype) to the problem being solved is a method for producing a preparation for increasing non-specific resistance and immunogenesis of an animal organism (PS-2), comprising mixing 0.2-0.3% agar suspension and a concentrate of a purified polysaccharide complex of yeast cells. To the resulting mixture, (-) 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole hydrochloride and formalin are added with constant stirring, the volume is adjusted to 100 parts by weight. The drug has immunostimulating activity (RU 2332214 C1, A61K 31/429, 31/115, A61K 36/06, A61K 36/02, A61P 37/04, 08/27/2008).

The disadvantages of the drug include the lack of antibacterial activity to animal pathogens.

The invention is directed to a preparation for activating nonspecific resistance, preventing and treating diseases of young farm animals, expanding the range of products both for increasing the activity of cellular and humoral links of nonspecific resistance and specific immunogenesis of the body, and for increasing antibacterial activity against pathogens of farm animals.

The technical result consists in mixing 90 wt.h. 0.2-0.3% suspension of agar and 2.5 wt.h. concentrate purified polysaccharide complex of yeast cells. To the resulting mixture, 3.5 parts by weight are added with constant stirring.

(-) 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole hydrochloride, 5.0 million units of the antibiotic amoxicillin and 0.2 parts by weight formalin, the volume is adjusted to 100 parts by weight The resulting preparation is poured into 50-100 ml bottles, after sterilization they are used to normalize non-specific resistance and immunogenesis, prevention and treatment of diseases of young farm animals.

The difference of the proposed solution from the known analogue is that with the introduction of the antibiotic amoxicillin together with the polysaccharide complex and

(-) 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole hydrochloride enhances their effect both on factors of nonspecific resistance and immunogenesis, and phagocytosis is activated and bactericidal activity against pathogens of young animals is enhanced .

To implement the method used the following substances:

1) microbiological agar GOST 17206;

2) the concentrate of the purified polysaccharide complex of yeast SU 1808331;

3) (-) 2,3,5,6-tetrahydro-6-phenylimidazo [2.1-b] thiazole hydrochloride TU 9333-024;

4) amoxicillin, registration number 002576 / 01-2003, 002576 / 02-2003;

5) formalin GOST 1625;

6) distilled water GOST 6709.

The method is as follows.

Example 1. 90 parts by weight 0.2% agar suspension was mixed with 2.5 wt.h. concentrate purified polysaccharide complex. To the resulting mixture, 3.5 parts by weight were added with constant stirring. (-) 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole hydrochloride, 5.0 million units of amoxicillin and 0.2 parts by weight formalin, the volume was adjusted to 100 parts by weight The resulting preparation after sterilization was used to normalize nonspecific resistance and immunogenesis, prevention and therapy of young animals' diseases.

Example 2. 90 parts by weight 0.3% agar suspension was mixed with 2.5 wt.h. concentrate purified polysaccharide complex. To the resulting mixture, 3.5 parts by weight were added with constant stirring. (-) 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole hydrochloride, 5.0 million units of the antibiotic amoxicillin and 0.2 wt.h. formalin, the volume was adjusted to 100 parts by weight The resulting preparation after sterilization was used to normalize nonspecific resistance and immunogenesis, prevention and treatment of young diseases.

The effectiveness of the drug obtained by the claimed method was determined in the economy, dysfunctional in acute diarrheal inflammatory processes in piglets, due to conditionally pathogenic and pathogenic microflora.

Example 3. The test of the drug was carried out on pigs, selected on the basis of pair-analogues, aged 60-65 days. Four groups of animals were created with 5 animals each. The pigs of the first group were injected with the preparation PS-2 (prototype) at a dose of 0.1 ml / kg of weight, the second group with the drug of the invention (example 1) at a dose of 0.1 ml / kg of weight, the third group with the drug of the invention (example 2 ) at a dose of 0.1 ml / kg of weight (experimental options). The fourth group was a control. 14 days after the administration of the drugs, the indicators of nonspecific resistance and immunogenesis of the organism were determined according to generally accepted research methods. The research results are shown in table 1.

It was found that the proposed drug improves hematopoiesis, as evidenced by an increase in the content of red blood cells by 15.1-16.9%, lymphocytes by 19.3-20.0%, and hemoglobin levels by 13.1-14.9%. An improvement in nonspecific resistance was noted: lysozyme activity of blood serum by 61.1-64.1% and bactericidal activity of blood serum by 67.3-76.2%, as well as the level of γ-globulins by 57.6-75.5%. The drug improves cellular factors of immunogenesis, as evidenced by an increase in the activity of T-lymphocytes by 15.6-19.4%.

Example 4. The test drug to study the prophylactic and therapeutic efficacy was carried out on suckling pigs, selected on the basis of pairs of analogues, at the age of 1-3 days. Four groups of animals were created with 12 animals each. The first group of piglets was injected with the preparation PS-2 (prototype) at a dose of 0.1 ml / kg of weight, the second group - with the drug of the invention (example 1) at a dose of 0.1 ml / kg of weight, the third group with the drug of the invention (example 2 ) at a dose of 0.1 ml / kg of weight (experimental options). The fourth group was a control. We studied the incidence and safety of piglets for 60 days. The results of these studies are shown in table.2.

table 2 The incidence and safety of piglets Indicators 1 group (prototype) Experienced group Control group the preparation of example 1 the preparation of example 2 Number of piglets 12 12 12 12 Got sick 3 3 3 5 Recovered 3 3 3 2 Pali 0 0 0 3 The duration of the disease, days 2.9 ± 0.3 3.7 ± 0.5 2.1 ± 0.5 7.6 ± 0.5 Incidence,% 25.0 25.0 25.0 41.7 Preservation,% one hundred one hundred one hundred 75

It was established that in the control group 5 piglets or 41.7% fell ill, of which 3 piglets fell and 2 recovered. Initially, piglets showed signs of acute inflammation of the intestinal tract (diarrhea), which manifested by diarrhea, turning into toxic dyspepsia with signs of dehydration and escherichiosis. The duration of the disease was 7.6 ± 0.5 days. In laboratory studies of the material from dead piglets, Escherichia, streptococcus, Proteus were isolated. Complications during the illness in piglets occur as a result of a decrease in the protective properties of the body, in which the activity of the conditionally pathogenic microflora (Escherichia, streptococci, protea) increases and the disease becomes toxic with signs of dehydration and escherichiosis.

The incidence of piglets in the 1st, 2nd and 3rd experimental groups was 25.0%, which is 1.7 times less than in the control. Their disease was accompanied by signs of depression, minor digestive disorders. In the treatment of the proposed methods, the piglets recovered within 3-6 days. The safety of piglets in the experimental groups was 100%. The additional inclusion of the antibiotic amoxicillin in the composition of the drug neutralizes possible pathogens of young animals, which is manifested by an increase in the prophylactic and therapeutic effectiveness of the proposed method.

Thus, on the basis of hematological, biochemical and immunological studies, it was found that the use of the proposed drug improves the parameters of nonspecific resistance and specific immunity of the animal organism and has prophylactic and therapeutic efficacy in diseases of the gastrointestinal tract of young farm animals.

Claims (1)

A method of obtaining a drug for enhancing non-specific resistance, prevention and treatment of diseases of young farm animals, comprising mixing agar suspension, concentrate of purified polysaccharide complex, (-) 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] -thiazole hydrochloride and formalin, characterized in that when mixing is additionally introduced 5.0 million UNITS of the antibiotic amoxicillin and the volume of the drug is adjusted to 100 parts by weight